Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Nanoliposome targeting in breast cancer is influenced by the tumor microenvironment.

Dumont N, Merrigan S, Turpin J, Lavoie C, Papavasiliou V, Geretti E, Espelin CW, Luus L, Kamoun WS, Ghasemi O, Sahagian GG, Muller WJ, Hendriks BS, Wickham TJ, Drummond DC.

Nanomedicine. 2019 Apr;17:71-81. doi: 10.1016/j.nano.2018.12.010. Epub 2019 Jan 14.

PMID:
30654182
2.

Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study.

Munster P, Krop IE, LoRusso P, Ma C, Siegel BA, Shields AF, Molnár I, Wickham TJ, Reynolds J, Campbell K, Hendriks BS, Adiwijaya BS, Geretti E, Moyo V, Miller KD.

Br J Cancer. 2018 Oct;119(9):1086-1093. doi: 10.1038/s41416-018-0235-2. Epub 2018 Oct 26.

PMID:
30361524
3.

Companion Diagnostic 64Cu-Liposome Positron Emission Tomography Enables Characterization of Drug Delivery to Tumors and Predicts Response to Cancer Nanomedicines.

Lee H, Gaddy D, Ventura M, Bernards N, de Souza R, Kirpotin D, Wickham T, Fitzgerald J, Zheng J, Hendriks BS.

Theranostics. 2018 Mar 21;8(9):2300-2312. doi: 10.7150/thno.21670. eCollection 2018.

4.

64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer.

Lee H, Shields AF, Siegel BA, Miller KD, Krop I, Ma CX, LoRusso PM, Munster PN, Campbell K, Gaddy DF, Leonard SC, Geretti E, Blocker SJ, Kirpotin DB, Moyo V, Wickham TJ, Hendriks BS.

Clin Cancer Res. 2017 Aug 1;23(15):4190-4202. doi: 10.1158/1078-0432.CCR-16-3193. Epub 2017 Mar 15.

5.

HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.

Miller K, Cortes J, Hurvitz SA, Krop IE, Tripathy D, Verma S, Riahi K, Reynolds JG, Wickham TJ, Molnar I, Yardley DA.

BMC Cancer. 2016 Jun 3;16:352. doi: 10.1186/s12885-016-2385-z.

6.

Dual HER2 Targeting with Trastuzumab and Liposomal-Encapsulated Doxorubicin (MM-302) Demonstrates Synergistic Antitumor Activity in Breast and Gastric Cancer.

Espelin CW, Leonard SC, Geretti E, Wickham TJ, Hendriks BS.

Cancer Res. 2016 Mar 15;76(6):1517-27. doi: 10.1158/0008-5472.CAN-15-1518. Epub 2016 Jan 12.

7.

Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302).

Geretti E, Leonard SC, Dumont N, Lee H, Zheng J, De Souza R, Gaddy DF, Espelin CW, Jaffray DA, Moyo V, Nielsen UB, Wickham TJ, Hendriks BS.

Mol Cancer Ther. 2015 Sep;14(9):2060-71. doi: 10.1158/1535-7163.MCT-15-0314. Epub 2015 Jul 10.

8.

Whole-body organ-level and kidney micro-dosimetric evaluations of (64)Cu-loaded HER2/ErbB2-targeted liposomal doxorubicin ((64)Cu-MM-302) in rodents and primates.

Gaddy DF, Lee H, Zheng J, Jaffray DA, Wickham TJ, Hendriks BS.

EJNMMI Res. 2015 Apr 14;5:24. doi: 10.1186/s13550-015-0096-0. eCollection 2015.

9.

Proteomic signatures of serum albumin-bound proteins from stroke patients with and without endovascular closure of PFO are significantly different and suggest a novel mechanism for cholesterol efflux.

Lopez MF, Krastins B, Sarracino DA, Byram G, Vogelsang MS, Prakash A, Peterman S, Ahmad S, Vadali G, Deng W, Inglessis I, Wickham T, Feeney K, Dec GW, Palacios I, Buonanno FS, Lo EH, Ning M.

Clin Proteomics. 2015 Jan 13;12(1):2. doi: 10.1186/1559-0275-12-2. eCollection 2015.

10.

A gradient-loadable (64)Cu-chelator for quantifying tumor deposition kinetics of nanoliposomal therapeutics by positron emission tomography.

Lee H, Zheng J, Gaddy D, Orcutt KD, Leonard S, Geretti E, Hesterman J, Harwell C, Hoppin J, Jaffray DA, Wickham T, Hendriks BS, Kirpotin D.

Nanomedicine. 2015 Jan;11(1):155-65. doi: 10.1016/j.nano.2014.08.011. Epub 2014 Sep 6.

PMID:
25200610
11.

Single-cell quantitative HER2 measurement identifies heterogeneity and distinct subgroups within traditionally defined HER2-positive patients.

Onsum MD, Geretti E, Paragas V, Kudla AJ, Moulis SP, Luus L, Wickham TJ, McDonagh CF, MacBeath G, Hendriks BS.

Am J Pathol. 2013 Nov;183(5):1446-1460. doi: 10.1016/j.ajpath.2013.07.015. Epub 2013 Sep 11.

PMID:
24035511
12.

Impact of tumor HER2/ERBB2 expression level on HER2-targeted liposomal doxorubicin-mediated drug delivery: multiple low-affinity interactions lead to a threshold effect.

Hendriks BS, Klinz SG, Reynolds JG, Espelin CW, Gaddy DF, Wickham TJ.

Mol Cancer Ther. 2013 Sep;12(9):1816-28. doi: 10.1158/1535-7163.MCT-13-0180. Epub 2013 May 30.

13.

HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity.

Reynolds JG, Geretti E, Hendriks BS, Lee H, Leonard SC, Klinz SG, Noble CO, Lücker PB, Zandstra PW, Drummond DC, Olivier KJ Jr, Nielsen UB, Niyikiza C, Agresta SV, Wickham TJ.

Toxicol Appl Pharmacol. 2012 Jul 1;262(1):1-10. doi: 10.1016/j.taap.2012.04.008. Epub 2012 Apr 21.

PMID:
22676972
14.

Multiscale kinetic modeling of liposomal Doxorubicin delivery quantifies the role of tumor and drug-specific parameters in local delivery to tumors.

Hendriks BS, Reynolds JG, Klinz SG, Geretti E, Lee H, Leonard SC, Gaddy DF, Espelin CW, Nielsen UB, Wickham TJ.

CPT Pharmacometrics Syst Pharmacol. 2012 Nov 21;1:e15. doi: 10.1038/psp.2012.16.

15.

Experimental treatment of ovarian cancers by adenovirus vectors combining receptor targeting and selective expression of tumor necrosis factor.

Murugesan SR, Akiyama M, Einfeld DA, Wickham TJ, King CR.

Int J Oncol. 2007 Oct;31(4):813-22.

PMID:
17786312
16.

Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity.

Krause A, Joh JH, Hackett NR, Roelvink PW, Bruder JT, Wickham TJ, Kovesdi I, Crystal RG, Worgall S.

J Virol. 2006 Jun;80(11):5523-30.

17.
18.

Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid.

Worgall S, Krause A, Rivara M, Hee KK, Vintayen EV, Hackett NR, Roelvink PW, Bruder JT, Wickham TJ, Kovesdi I, Crystal RG.

J Clin Invest. 2005 May;115(5):1281-9. Epub 2005 Apr 1.

19.

Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells.

Sachs MD, Ramamurthy M, Poel Hv, Wickham TJ, Lamfers M, Gerritsen W, Chowdhury W, Li Y, Schoenberg MP, Rodriguez R.

Cancer Gene Ther. 2004 Jul;11(7):477-86.

PMID:
15118762
20.

Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses.

Worgall S, Busch A, Rivara M, Bonnyay D, Leopold PL, Merritt R, Hackett NR, Rovelink PW, Bruder JT, Wickham TJ, Kovesdi I, Crystal RG.

J Virol. 2004 Mar;78(5):2572-80.

21.
22.

Binding of adenoviral fiber knob to the coxsackievirus-adenovirus receptor is crucial for transduction of fetal muscle.

Bilbao R, Srinivasan S, Reay D, Goldberg L, Hughes T, Roelvink PW, Einfeld DA, Wickham TJ, Clemens PR.

Hum Gene Ther. 2003 May 1;14(7):645-9.

PMID:
12804146
23.

The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors.

Liu Q, Zaiss AK, Colarusso P, Patel K, Haljan G, Wickham TJ, Muruve DA.

Hum Gene Ther. 2003 May 1;14(7):627-43.

PMID:
12804145
24.

Gamma-irradiation enhances transgene expression in leukemic cells.

Vereecque R, Saudemont A, Wickham TJ, Gonzalez R, Hetuin D, Fenaux P, Quesnel B.

Gene Ther. 2003 Feb;10(3):227-33.

PMID:
12571630
25.

Ligand-directed targeting of genes to the site of disease.

Wickham TJ.

Nat Med. 2003 Jan;9(1):135-9. Review. No abstract available.

PMID:
12514727
26.

Selective gene transfer into primary human gastric tumors using epithelial cell adhesion molecule-targeted adenoviral vectors with ablated native tropism.

Heideman DA, van Beusechem VW, Offerhaus GJ, Wickham TJ, Roelvink PW, Craanen ME, Pinedo HM, Meijer CJ, Gerritsen WR.

Hum Gene Ther. 2002 Sep 20;13(14):1677-85.

PMID:
12396621
27.

Modifications in adenoviral coat fiber proteins and transcriptional regulatory sequences enhance transgene expression.

Perlman H, Liu H, Georganas C, Woods JM, Amin MA, Koch AE, Wickham T, Kovesdi I, Mano T, Walsh K, Pope RM.

J Rheumatol. 2002 Aug;29(8):1593-600.

PMID:
12180715
29.

Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished.

van Beusechem VW, Grill J, Mastenbroek DC, Wickham TJ, Roelvink PW, Haisma HJ, Lamfers ML, Dirven CM, Pinedo HM, Gerritsen WR.

J Virol. 2002 Mar;76(6):2753-62.

30.

Head injuries in infants: the risks of bouncy chairs and car seats.

Wickham T, Abrahamson E.

Arch Dis Child. 2002 Mar;86(3):168-9.

31.

Activation of p38 and ERK signaling during adenovirus vector cell entry lead to expression of the C-X-C chemokine IP-10.

Tibbles LA, Spurrell JC, Bowen GP, Liu Q, Lam M, Zaiss AK, Robbins SM, Hollenberg MD, Wickham TJ, Muruve DA.

J Virol. 2002 Feb;76(4):1559-68.

32.

Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions.

Einfeld DA, Schroeder R, Roelvink PW, Lizonova A, King CR, Kovesdi I, Wickham TJ.

J Virol. 2001 Dec;75(23):11284-91.

33.

Transduction and apoptosis induction in the rat prostate, using adenovirus vectors.

Kirkman W 3rd, Chen P, Schroeder R, Feneley MR, Rodriguez R, Wickham TJ, King CR, Bruder JT.

Hum Gene Ther. 2001 Aug 10;12(12):1499-512.

PMID:
11506693
34.

Adenovirus type 9 fiber knob binds to the coxsackie B virus-adenovirus receptor (CAR) with lower affinity than fiber knobs of other CAR-binding adenovirus serotypes.

Kirby I, Lord R, Davison E, Wickham TJ, Roelvink PW, Kovesdi I, Sutton BJ, Santis G.

J Virol. 2001 Aug;75(15):7210-4.

36.

The role of receptors in the maturation-dependent adenoviral transduction of myofibers.

Cao B, Pruchnic R, Ikezawa M, Xiao X, Li J, Wickham TJ, Kovesdi I, Rudert WA, Huard J.

Gene Ther. 2001 Apr;8(8):627-37.

37.

Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells.

Cripe TP, Dunphy EJ, Holub AD, Saini A, Vasi NH, Mahller YY, Collins MH, Snyder JD, Krasnykh V, Curiel DT, Wickham TJ, DeGregori J, Bergelson JM, Currier MA.

Cancer Res. 2001 Apr 1;61(7):2953-60.

38.

Extended tropism of an adenoviral vector does not circumvent the maturation-dependent transducibility of mouse skeletal muscle.

van Deutekom JC, Cao B, Pruchnic R, Wickham TJ, Kovesdi I, Huard J.

J Gene Med. 1999 Nov-Dec;1(6):393-9.

PMID:
10753064
39.

Receptor-mediated targeting of gene delivery vectors: insights from molecular mechanisms for improved vehicle design.

Varga CM, Wickham TJ, Lauffenburger DA.

Biotechnol Bioeng. 2000 Dec 20;70(6):593-605. Review.

PMID:
11064328
40.

A novel approach and a novel mechanism for stealthing gene delivery vehicles.

Wickham T.

Mol Ther. 2000 Aug;2(2):103-4. No abstract available.

41.

Adenovirus as a gene therapy vector for hematopoietic cells.

Marini FC 3rd, Yu Q, Wickham T, Kovesdi I, Andreeff M.

Cancer Gene Ther. 2000 Jun;7(6):816-25. Review.

42.

Efficient adenoviral gene transfer to kidney cortical vasculature utilizing a fiber modified vector.

McDonald GA, Zhu G, Li Y, Kovesdi I, Wickham TJ, Sukhatme VP.

J Gene Med. 1999 Mar-Apr;1(2):103-10.

PMID:
10738574
43.

Modifications of the fiber in adenovirus vectors increase tropism for malignant glioma models.

Staba MJ, Wickham TJ, Kovesdi I, Hallahan DE.

Cancer Gene Ther. 2000 Jan;7(1):13-9.

44.

Identification of contact residues and definition of the CAR-binding site of adenovirus type 5 fiber protein.

Kirby I, Davison E, Beavil AJ, Soh CP, Wickham TJ, Roelvink PW, Kovesdi I, Sutton BJ, Santis G.

J Virol. 2000 Mar;74(6):2804-13.

45.

Targeting adenovirus.

Wickham TJ.

Gene Ther. 2000 Jan;7(2):110-4. Review.

46.

Optimizing cardiovascular gene therapy: increased vascular gene transfer with modified adenoviral vectors.

Kibbe MR, Murdock A, Wickham T, Lizonova A, Kovesdi I, Nie S, Shears L, Billiar TR, Tzeng E.

Arch Surg. 2000 Feb;135(2):191-7.

PMID:
10668880
47.

Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae.

Roelvink PW, Mi Lee G, Einfeld DA, Kovesdi I, Wickham TJ.

Science. 1999 Nov 19;286(5444):1568-71.

48.

Transduction of bone marrow cells by the AdZ.F(pK7) modified adenovirus demonstrates preferential gene transfer in myeloma cells.

Gonzalez R, Vereecque R, Wickham TJ, Facon T, Hetuin D, Kovesdi I, Bauters F, Fenaux P, Quesnel B.

Hum Gene Ther. 1999 Nov 1;10(16):2709-17.

PMID:
10566899
49.

Mutations in the DG loop of adenovirus type 5 fiber knob protein abolish high-affinity binding to its cellular receptor CAR.

Kirby I, Davison E, Beavil AJ, Soh CP, Wickham TJ, Roelvink PW, Kovesdi I, Sutton BJ, Santis G.

J Virol. 1999 Nov;73(11):9508-14.

50.

Construction of a pseudoreceptor that mediates transduction by adenoviruses expressing a ligand in fiber or penton base.

Einfeld DA, Brough DE, Roelvink PW, Kovesdi I, Wickham TJ.

J Virol. 1999 Nov;73(11):9130-6.

Supplemental Content

Loading ...
Support Center